Skip to content
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil BB.
Prostate. 2022 Oct 7. doi: 10.1002/pros.24447. Epub ahead of print.
Emerging Targeted Therapies for Early Breast Cancer.
Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM.
Drugs. 2022 Oct 7. doi: 10.1007/s40265-022-01781-5. Epub ahead of print.
Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil BB.
Prostate. 2022 Oct 7. doi: 10.1002/pros.24447. Epub ahead of print.
Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
Emerging Targeted Therapies for Early Breast Cancer.
Schlam I, Tarantino P, Morganti S, Lynce F, Trapani D, Mayer EL, Garrido-Castro AC, Waks A, Tolaney SM.
Drugs. 2022 Oct 7. doi: 10.1007/s40265-022-01781-5. Epub ahead of print.
Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil BB.
Prostate. 2022 Oct 7. doi: 10.1002/pros.24447. Epub ahead of print.
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer.
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, Cortes J, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D.
Cancer Treat Rev. 2022 Sep 28;111:102468. doi: 10.1016/j.ctrv.2022.102468. Epub ahead of print.